Market capitalization | $4.56b |
Enterprise Value | $4.02b |
P/E (TTM) P/E ratio | 14.36 |
EV/FCF (TTM) EV/FCF | 12.75 |
EV/Sales (TTM) EV/Sales | 2.67 |
P/S ratio (TTM) P/S ratio | 3.03 |
P/B ratio (TTM) P/B ratio | 3.53 |
Revenue growth (TTM) Revenue growth | -5.37% |
Revenue (TTM) Revenue | $1.51b |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
13 Analysts have issued a Alkermes Plc forecast:
13 Analysts have issued a Alkermes Plc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,505 1,505 |
5%
5%
|
|
Gross Profit | 1,238 1,238 |
5%
5%
|
|
EBITDA | 352 352 |
21%
21%
|
EBIT (Operating Income) EBIT | 313 313 |
45%
45%
|
Net Profit | 333 333 |
55%
55%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Richard Pops |
Employees | 2,100 |
Founded | 2011 |
Website | www.alkermes.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.